CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.00 USD
+0.03 (2.72%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.99 -0.01 (-1.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CARM 1.00 +0.03(2.72%)
Will CARM be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARM
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Other News for CARM
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly
Warning: CARM is at high risk of performing badly